Sign up
Pharma Capital

Anatara Lifesciences transitions gut health focus from animals to humans

Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steven Lydeamore speaks to Proactive Investors about the healthcare company's renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).
 
Lydeamore says the biotech firm's dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.
 
Anatara Lifesciences first came to prominence in developing a product to reduce diarrhoea in livestock.
 

View full ANR profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.